Shares of OncoSec Medical (NASDAQ:ONCS) have been assigned an average recommendation of “Buy” from the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $4.50.

A number of analysts have issued reports on ONCS shares. Piper Jaffray Companies started coverage on OncoSec Medical in a research report on Friday, February 9th. They issued an “overweight” rating and a $4.00 target price for the company. Maxim Group set a $5.00 target price on OncoSec Medical and gave the stock a “buy” rating in a research report on Thursday, March 15th. HC Wainwright decreased their target price on OncoSec Medical from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, April 23rd. Finally, ValuEngine raised OncoSec Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

OncoSec Medical traded up $0.08, reaching $1.67, during mid-day trading on Friday, MarketBeat reports. 528,279 shares of the company’s stock were exchanged, compared to its average volume of 825,209. The firm has a market capitalization of $85.97 million, a P/E ratio of -1.58 and a beta of 3.05. OncoSec Medical has a one year low of $0.88 and a one year high of $2.95.

OncoSec Medical (NASDAQ:ONCS) last issued its quarterly earnings results on Friday, March 9th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05). research analysts anticipate that OncoSec Medical will post -0.79 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC grew its position in shares of OncoSec Medical by 2,073.8% in the first quarter. Millennium Management LLC now owns 1,000,576 shares of the biotechnology company’s stock valued at $1,881,000 after purchasing an additional 954,547 shares in the last quarter. Nexthera Capital LP purchased a new position in shares of OncoSec Medical in the first quarter valued at $3,881,000. Point72 Asset Management L.P. grew its position in shares of OncoSec Medical by 47.5% in the first quarter. Point72 Asset Management L.P. now owns 3,215,000 shares of the biotechnology company’s stock valued at $6,044,000 after purchasing an additional 1,035,000 shares in the last quarter. venBio Select Advisor LLC purchased a new position in shares of OncoSec Medical in the first quarter valued at $7,534,000. Finally, Sofinnova Ventures Inc purchased a new position in shares of OncoSec Medical in the first quarter valued at $126,000. Institutional investors own 26.49% of the company’s stock.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.